MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Total Liabilities 2011-2026 | OPK
Annual Total Liabilities OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 835 M | 622 M | 606 M | 715 M | 802 M | 695 M | 660 M | 699 M | 675 M | 820 M | 432 M | 519 M | 86.6 M | 68.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 835 M | 68.6 M | 588 M |
Quarterly Total Liabilities OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 676 M | 817 M | 853 M | 585 M | 721 M | 612 M | 624 M | 618 M | 606 M | 596 M | - | 692 M | 715 M | 652 M | 679 M | 823 M | 802 M | 802 M | 802 M | 802 M | 695 M | 695 M | 695 M | 695 M | 660 M | 660 M | 660 M | 660 M | 746 M | 734 M | 734 M | 734 M | 720 M | 675 M | 675 M | 675 M | 819 M | 819 M | 819 M | 819 M | 432 M | 432 M | 432 M | 432 M | 519 M | 519 M | 519 M | 519 M | 86.6 M | 86.6 M | 86.6 M | 86.6 M | 44.2 M | 44.2 M | 44.2 M | 44.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 853 M | 44.2 M | 585 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioNano Genomics
BNGO
|
29.2 M | $ 1.14 | 0.88 % | $ 6.21 M |  USA |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
433 M | $ 16.07 | -0.28 % | $ 173 M |  China |
 |
Agilent Technologies
A
|
5.32 B | $ 116.09 | 0.88 % | $ 35.3 B | USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 16.43 | 2.34 % | $ 876 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 2.23 | -3.26 % | $ 9.87 M | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 1.38 | 0.74 % | $ 1.84 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 22.86 | -1.17 % | $ 635 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 178.59 | 1.66 % | $ 8.85 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 495.8 | 0.46 % | $ 14.3 B | USA |
 |
Danaher Corporation
DHR
|
31.8 B | $ 192.99 | 1.8 % | $ 138 B | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.51 | 3.79 % | $ 418 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 7.89 | 2.54 % | $ 1.01 B | USA |
 |
Illumina
ILMN
|
2.7 B | $ 123.69 | 2.28 % | $ 19.7 B | USA |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 15.14 | 4.92 % | $ 458 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 79.27 | 0.85 % | $ 9.94 B | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 2.8 | 4.08 % | $ 90.9 K | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.07 | -3.5 % | $ 4.75 M | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 28.38 | 0.26 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 109.1 | 2.14 % | $ 9 B |  Irlanda |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 6.65 | -0.45 % | $ 277 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 262.3 | 0.53 % | $ 21.8 B | USA |
 |
Natera
NTRA
|
689 M | $ 197.28 | 2.2 % | $ 19.4 B | USA |
 |
Celcuity
CELC
|
366 M | $ 118.07 | 0.79 % | $ 5.52 B | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 80.94 | 0.43 % | $ 5.46 B | USA |
 |
Soleno Therapeutics
SLNO
|
114 M | $ 52.65 | 0.04 % | $ 2.68 B | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 190.76 | -0.4 % | $ 21.2 B | USA |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 9.15 | -2.81 % | $ 1.98 B | USA |
 |
ENDRA Life Sciences
NDRA
|
1.59 M | $ 5.0 | 1.21 % | $ 3.94 M | USA |
 |
Neuronetics
STIM
|
115 M | $ 1.4 | 3.33 % | $ 92.3 M | USA |